Asoluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties

Blood

Volumn 107, Issue 3, 2006, Pages 980-986

  Huang, Xin ^b   Ding, Wei Qun ^b   Vaught, Joshua L ^b   Wolf, Roman F ^b   Morrissey, James H ^b   Harrison, Roger G ^b   Lind, Stuart E ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; CHIMERIC PROTEIN; COMPLEMENTARY DNA; ENOXAPARIN; HEPARIN; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8A; COAGULATING AGENT; HYBRID PROTEIN; PHOSPHATIDYLSERINE;

ANIMAL CELL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; BLOOD VESSEL INJURY; CONTROLLED STUDY; HEMOSTASIS; LIGAND BINDING; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; ANIMAL; BLEEDING; BLOOD VESSEL; DOSE RESPONSE; DRUG EFFECT; GENETICS; HUMAN; INJURY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PROTEIN TERTIARY STRUCTURE; VASCULARIZATION;

ANIMALS; ANNEXIN A5; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD VESSELS; COAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIIA; FACTOR X; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLSERINES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; THROMBOPLASTIN;

EID: 31544434253     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-07-2733     Document Type: Article

References (52)

1. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087-1097.
2. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem. 1991;266:2158-2166.
3. Neuenschwander PF, Morrissey JH. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function: analysis of a mutant with a selective deficiency in activity. J Biol Chem. 1992;267:14477-14482.
4. Paborsky LR, Caras IW, Fisher KL, Gorman CM. Lipid association, but not the transmembrane domain, is required for tissue factor activity: substitution of the transmembrane domain with a phosphatidylinositol anchor. J Biol Chem. 1991;266:21911-21916.
5. Macfarlane RG, Biggs R. A thrombin generation test: the application in haemophilia and thrombocytopenia. J Clin Pathol. 1953;6:3-8.
6. Caen J, Bellucci S. The defective prothrombin consumption in Bernard-Soulier syndrome: hypotheses from 1948 to 1982. Blood Cells. 1983;9:389-399.
7. Rosing J, Bevers EM, Comfurius P, et al. Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood. 1985;65:1557-1561.
8. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest. 1996;98:863-874.
9. Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol. 2004;11:170-175.
10. Thomas L. Studies on the intravacular thromboplastin effect of tissue suspensions in mice: II, a factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component. Bull Johns Hopkins Hosp. 1947;81:26-42.
11. Gitel SN, Wessler S. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications. J Lab Clin Med. 1979;94:481-488.
12. Morrissey JH, Comp PC. Treatment of bleeding with modified tissue factor in combination with FVIIa. US Patent 5,374,617. May 13, 1992.
13. Thiagarajan P, Tait JF. Binding of annexin V/placental anticoagulant protein I to platelets: evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem. 1990;265:17420-17423.
14. Satta N, Toti F, Feugeas O, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol. 1994;153:3245-3255.
15. van Heerde WL, Poort S, van 't Veer C, Reutelingsperger CP, de Groot PG. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem J. 1994;302(pt 1):305-312.
16. Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem. 1989;264:7944-7949.
17. Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry. 1995;34:13988-13993.
18. Rezaie AR, Fiore MM, Neuenschwander PF, Esmon CT, Morrissey JH. Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody. Protein Expr Purif. 1992;3:453-460.
19. Morrissey JH, Fair DS, Edgington TS. Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res. 1988;52:247-261.
20. Gabriel NE, Roberts MF. Spontaneous formation of stable unilamellar vesicles. Biochemistry. 1984;23:4011-4015.
21. Chen PS, Toribara TY, Warner H. Microdetermination of phosphorus. Analyt Chem. 1956;28:1756-1758.
22. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry. 1981;20:833-840.
23. Neuenschwander PF, Fiore MM, Morrissey JH. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes: implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem. 1993;268:21489-21492.
24. Kelley RF, Refino CJ, O'Connell MP, et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood. 1997;89:3219-3227.
25. Tait JF, Engelhardt S, Smith C, Fujikawa K. Prourokinase-annexin V chimeras: construction, expression, and characterization of recombinant proteins. J Biol Chem. 1995;270:21594-21599.
26. Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004;104:2783-2790.
27. Huang Q, Neuenschwander PF, Rezaie AR, Morrissey JH. Substrate recognition by tissue factor-factor VIIa: evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X. J Biol Chem. 1996;271:21752-21757.
28. Yamamoto M, Nakagaki T, Kisiel W. Tissue factordependent autoactivation of human blood coagulation factor VII. J Biol Chem. 1992;267:19089-19094.
29. Fiore MM, Neuenschwander PF, Morrissey JH. The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa. J Biol Chem. 1994;269:143-149.
30. Morrissey JH, Neuenschwander PF, Huang Q, McCallum CD, Su B, Johnson AE. Factor VIIa-tissue factor: functional importance of protein-membrane interactions. Thromb Haemost. 1997;78:112-116.
31. al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost. 2004;2:1395-1401.
32. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol. 2004;41:35-39.
33. Dejana E, Quintana A, Callioni A, de Gaetano G. Bleeding time in laboratory animals: III, do tail bleeding times in rats only measure a platelet defect? (the aspirin puzzle). Thromb Res. 1979;15:199-207.
34. Dejana E, Callioni A, Quintana A, de Gaetano G. Bleeding time in laboratory animals: II, a comparison of different assay conditions in rats. Thromb Res. 1979;15:191-197.
35. Diness V, Lund-Hansen T, Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res. 1990;59:921-929.
36. Kung SH, Hagstrom JN, Cass D, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood. 1998;91:784-790.
37. Waxman E, Ross JB, Laue TM, et al. Tissue factor and its extracellular soluble domain: the relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry. 1992;31:3998-4003.
38. Huang X, Molema G, King S,Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997;275:547-550.
39. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 1998;58:4646-4653.
40. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001;61:711-716.
41. Liu C, Huang H, Donate F, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res. 2002;62:5470-5475.
42. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003;63:5046-5053.
43. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood. 2003;102:3615-3620.
44. Schatz S, Turecek PL, Fiedler C, et al. Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse model. Br J Haematol. 2003;123:692-695.
45. Nelsestuen GL, Stone M, Martinez MB, Harvey SB, Foster D, Kisiel W. Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes: behavior in a diffusion-limited reaction. J Biol Chem. 2001;276:39825-39831.
46. Rippmann JF, Pfizenmaier K, Mattes R, Rettig WJ, Moosmayer D. Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule. Biochem J. 2000;349(pt 3):805-812.
47. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys. 2002;54:1479-1484.
48. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62:6132-6140.
49. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002;8:2766-2774.
50. Mochizuki T, Kuge Y, Zhao S, et al. Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with (99m)Tc-Annexin V. J Nucl Med. 2003;44:92-97.
51. Takei T, Kuge Y, Zhao S, et al. Time course of apoptotic tumor response after a single dose of chemotherapy: comparison with 99mTc-Annexin V uptake and histologic findings in an experimental model. J Nucl Med. 2004;45:2083-2087.
52. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 2001;293:293-297.